Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.
F
F
Cervantes
C
C
Salgado
E
E
Montserrat
C
C
Rozman
D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D001402:B-Lymphocytes; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D015463:Leukemia, Prolymphocytic / Q000188:drug therapy*; D008297:Male; D011658:Pulmonary Fibrosis / Q000139:chemically induced*; D012307:Risk Factors; D001084:Vidarabine Phosphate / Q000009:adverse effects / Q000031:analogs & derivatives*
D000964:Antimetabolites, Antineoplastic; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate